Benjamin F. Edwards & Company, Inc. Sage Therapeutics, Inc. Transaction History

Benjamin F. Edwards & Company, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 04, 2022	SELL	$30.71 - $45.71 $5,619 - $8,364	-183 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$140.29 - $189.96 $7,014 - $9,498	50 Added 37.59%	183 $26,000
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $14,918 - $27,329	-167 Reduced 55.67%	133 $21,000
Q4 2018 Jan 31, 2019	BUY	$81.94 - $139.71 $24,582 - $41,913	300 New	300 $29,000

218

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.